Drugs / Somatotropin (Human)
Somatotropin (Human)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03091374 | Dec 2016 → Mar 2021 | HIV infectious disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Somatotropin (Human) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03091374 ↗ |
| Known as | recombinant human growth hormone | “Use of recombinant human growth hormone has been shown to improve immune function by several mechanisms.” NCT03091374 ↗ |
| Known as | rhGH | “Recombinant human growth hormone (rhGH) administered to ART-treated HIV infected individuals has been found to reverse thymic involution, increase total and naïve CD4 T cell...” NCT03091374 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection” NCT03091374 ↗ |